ARAKODA Drug Patent Profile

When do Arakoda patents expire, and what generic alternatives are available?

Arakoda is a drug marketed by 60 Degrees Pharms and is included in one NDA. There are four patents protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in ARAKODA is tafenoquine succinate. Two suppliers are listed for this compound. Additional details are available on the tafenoquine succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Arakoda

Arakoda was eligible for patent challenges on July 20, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 2, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ARAKODA

International Patents:	9
US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ARAKODA

ARAKODA is protected by four US patents.

This potential generic entry date is based on patent 10,342,791.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes	10,342,791
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes	12,616,689
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes	11,744,828
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes	10,888,558

International Patents for ARAKODA

When does loss-of-exclusivity occur for ARAKODA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Hong Kong

New Zealand

Singapore

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ARAKODA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015358566	Novel regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Australia	2020270452	Novel regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Canada	2968694	REGIMES A BASE DE TAFENOQUINE POUR LA PREVENTION DU PALUDISME CHEZ DES PERSONNES NON ATTEINTES DU PALUDISME (REGIMENS OF TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAIVE SUBJECTS)
China	107683278	用于在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 (Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na Ve Subjects)
European Patent Office	3212621	NOUVEAUX PROTOCOLES DE TRAITEMENT À BASE DE TAFÉNOQUINE POUR LA PRÉVENTION DU PALUDISME CHEZ DES PERSONNES NON-ATTEINTES DU PALUDISME (NOVEL REGIMENS OF TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAÏVE SUBJECTS)
Hong Kong	1243704	用於在未接觸瘧疾的受試者中預防瘧疾的他非諾喹的新方案 (NOVEL REGIMENS OF TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAÏVE SUBJECTS)
New Zealand	731813	Novel regimens of tafenoquine for prevention of malaria in malaria-naïve subjects

ARAKODA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

ARAKODA (also known as atovaquone/proguanil) is an antimalarial medication primarily used for malaria prevention and treatment. With growing global malaria burdens and expanding markets for prophylactic drugs in travel and endemic regions, ARAKODA presents a significant investment opportunity. This analysis evaluates current market dynamics, competitive landscape, regulatory environment, financial forecasts, and strategic considerations to guide stakeholders interested in ARAKODA’s commercial trajectory.

---

What Is the Market Size and Demand for ARAKODA?

Global Malaria Burden and Treatment Landscape

Metric	Figures	Source
Annual malaria cases worldwide	~241 million (WHO, 2021)	[1]
Endemic countries	85+ countries, primarily in Africa, Southeast Asia, Americas	[1]
Global antimalarial market size	USD 4.2 billion (2022 projection)	[2]
Prophylactic drug segment growth	CAGR 7.5% (2022-2027)	[2]

Target Segments

• Travel Medicine & Prophylaxis: Increasing international travel drives demand.
• Endemic Regions: Periodic government procurement for prophylaxis.
• Treatment Market: Less prevalent; primarily for preventatives.

Key Market Drivers

• Rising travel to malaria-endemic areas.
• Expanding portfolio of malaria prevention strategies.
• Growing awareness among travelers and military personnel.
• Favorable safety profile relative to alternatives.

---

Competitive Positioning & Market Dynamics

Major Competitors and Alternatives

Drug Name	Type	Advantages	Limitations
Doxycycline	Antibiotic prophylactic	Cost-effective, widespread use	Photosensitivity, gastrointestinal side effects
Mefloquine	Chemo-prophylactic agent	Once weekly dosing	Neuropsychiatric adverse effects
Tafenoquine	Single-dose prophylaxis	Convenience, long half-life	Contraindications in G6PD deficiency
Chloroquine	Historical use (limited)	Established, low cost	Resistance issues
ARAKODA	Fixed-dose combination	Good safety profile, wide coverage	Higher cost relative to generics

Market Dynamics

• Patent Status & Generic Competition: In many markets, atovaquone/proguanil transitioned to generic status post patent expiry, intensifying price competition.
• Patent and Exclusivity: Limited exclusivity in key markets limits barriers for generic entry, impacting pricing strategies.
• Pricing Strategies: Premium pricing in travel segments versus competitive pricing in endemic regions.
• Regulatory Landscape: WHO inclusion for specific formulations impacts procurement, especially in low-income settings.

---

Regulatory and Market Entry Considerations

Regulatory Approvals & Health Authority Status

Region	Status	Impact on Market Entry	Key Regulatory Agencies
United States	Approved by FDA (2001)	Established, high revenue potential	FDA
European Union	Approved via EMEA (EMA)	Facilitates access, reimbursement channels	EMA
Africa & Southeast Asia	Registered & procured via WHO and local authorities	Market growth in endemic nations	Local health ministries

Challenges

• Navigating complex registration processes.
• Addressing regional pricing and reimbursement policies.
• Competing with established generics.

---

Financial Trajectory & Investment Potential

Revenue Projections (2023–2028)

Year	Estimated Global Sales (USD millions)	Comments
2023	150	Sales driven by travel medicine and endemic procurement
2024	180	Increased acceptance, expanding markets
2025	210	Entry into new markets, international tenders
2026	240	Market penetration, price stabilization
2027	270	Maturation phase, steady growth

Profitability Estimates

Metrics	Assumptions
Gross Margin	55-60% (due to generic competition)
R&D Expenses	USD 10-15 million annually (for new formulations/regulations)
Operating Margin	15-20% (post-market expansion, cost efficiencies)

Investment Considerations

Factors	Impact on ROI
Market Growth Rate	Supports robust revenue increases
Patent Landscape	Limited exclusivity requires differentiation
Geographic Expansion Opportunities	Asia-Pacific, Latin America, Africa
Regulatory Strategy	Accelerated approvals via WHO prequalification

---

Comparison with Competing Drugs

Parameter	ARAKODA	Doxycycline	Mefloquine	Tafenoquine
Dosing Schedule	Once daily	Daily	Weekly	Single dose
Side Effect Profile	Mild, well-tolerated	Gastrointestinal, photosensitivity	Neuropsychiatric issues	G6PD contraindication
Resistance Potential	Low	Moderate	Low to moderate	Low
Cost per Treatment	USD 50–70 (brand), lower generic	USD 2–5 (generic)	USD 6–10	USD 70–100 (single dose)
Regulatory Status	Approved globally	Approved globally	Approved in select markets	Approved in select markets

---

Strategic Recommendations for Investors

• Capitalize on Growing Travel Market: Focus on regions with expanding outbound travel and willingness to pay premium for safety.
• Leverage Regulatory Approvals: Accelerate registration efforts in emerging markets, capitalize on WHO prequalification.
• Differentiate Product Offering: Emphasize safety, single-dose regimen (if applicable), and reduced side effects.
• Monitor Patent and Market Exclusivity: Time entries before generic dominance phase intensifies pricing pressure.
• Explore Partnership and Licensing: Collaborate with regional distributors and health agencies to penetrate endemic markets effectively.

---

Key Challenges and Risks

• Generic Competition: Ongoing patent expiries erode pricing power.
• Pricing Pressures: Governments and NGOs demand cost-effective options.
• Regulatory Delays: Regional registration hurdles.
• Resistance Development: Potential for resistance emergence affecting treatment efficacy.

---

Key Takeaways

• Market Potential: The global malaria prophylaxis market is projected to grow at a CAGR of 7.5%, driven by travel and endemic disease control efforts.
• Competitive Position: While priced higher than generics, ARAKODA's safety profile and dosing convenience afford competitive differentiation.
• Financial Outlook: Revenues are expected to steadily increase, with margins influenced heavily by generic competition and pricing strategies.
• Growth Opportunities: Key markets include North America, Europe, Africa, and Asia-Pacific, where expanding healthcare infrastructure and travel markets support growth.
• Risks & Challenges: Patent expiries, price competition, regulatory delays, and resistance issues require proactive management.

---

FAQs about ARAKODA Investment and Market Dynamics

Q1: What is the current patent status of ARAKODA?
ARAKODA’s primary patent protections expired in many jurisdictions by 2018–2020, leading to increased generic participation and price competition [3].

Q2: How does regulatory approval influence market entry?
Regulatory approval via authorities like the FDA, EMA, and WHO prequalification accelerates procurement, particularly in government and NGO sectors, creating revenue opportunities [1].

Q3: What are key strategic considerations for entering the endemic market?
Regulatory registration, partnerships with local health authorities, adherence to local protocols, and price competitiveness are essential for success.

Q4: How does resistance impact the long-term viability of ARAKODA?
Limited reports of resistance and low mutation rates for atovaquone/proguanil support sustained efficacy, but ongoing surveillance is critical.

Q5: What are the main differentiators of ARAKODA compared to alternatives?
Single-dose regimen, favorable safety profile, and proven efficacy, especially in G6PD-normal populations, differentiate it from other prophylactics.

---

References

[1] World Health Organization. "World malaria report 2021." WHO, 2021.
[2] Grand View Research. “Malaria Drugs Market Size & Trends.” 2022.
[3] U.S. Patent and Trademark Office. “Patent status of atovaquone/proguanil.” 2018.

---

In conclusion, ARAKODA remains a strategic asset within the malaria prophylaxis market. Its growth prospects hinge on geographic expansion, competitive positioning in price-sensitive markets, and regulatory pathways. Investors should balance growth opportunities with patent, pricing, and resistance risks to develop an informed, strategic approach.